Tarsus Pharmaceuticals, Inc.
TARS
$50.00
$0.030.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 182.95M | 129.62M | 83.37M | 42.56M | 17.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 182.95M | 129.62M | 83.37M | 42.56M | 17.45M |
| Cost of Revenue | 54.15M | 46.87M | 43.98M | 41.20M | 39.55M |
| Gross Profit | 128.81M | 82.75M | 39.39M | 1.36M | -22.10M |
| SG&A Expenses | 237.31M | 211.29M | 183.70M | 145.18M | 108.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 303.52M | 270.22M | 239.75M | 198.45M | 160.61M |
| Operating Income | -120.57M | -140.60M | -156.37M | -155.89M | -143.16M |
| Income Before Tax | -115.55M | -134.34M | -150.07M | -148.21M | -135.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -115.55 | -134.34 | -150.07 | -148.21 | -135.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.55M | -134.34M | -150.07M | -148.21M | -135.89M |
| EBIT | -120.57M | -140.60M | -156.37M | -155.89M | -143.16M |
| EBITDA | -119.34M | -139.46M | -155.27M | -154.85M | -142.28M |
| EPS Basic | -3.10 | -3.81 | -4.48 | -4.77 | -4.64 |
| Normalized Basic EPS | -1.85 | -2.29 | -2.70 | -2.92 | -2.85 |
| EPS Diluted | -3.10 | -3.81 | -4.48 | -4.77 | -4.64 |
| Normalized Diluted EPS | -1.85 | -2.29 | -2.70 | -2.92 | -2.85 |
| Average Basic Shares Outstanding | 150.07M | 143.45M | 135.69M | 124.68M | 116.12M |
| Average Diluted Shares Outstanding | 150.07M | 143.45M | 135.69M | 124.68M | 116.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |